Lab
Privilege DX Medical Laboratories, INC.
Privilege DX Medical Laboratories, INC. was paid $261K by Medicaid between Jan 2018 and Nov 2024, across 69 billing codes. Its largest line is 85025, Blood count; complete (CBC), automated, and automated differential WBC count — 6.2% of everything it billed.
33Billing provider infoPRIVILEGE DX MEDICAL LABORATORIES, INC.
TOLUCA LAKE, CA 91602
TOLUCA LAKE, CA 91602
33aNPI1003369968assigned 07/27/2016
33bProvider typeClinical Medical Laboratory
28Total paid$261K
24GClaims218,841
24DCodes billed69
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#271 of 561
Median peer was paid$222K
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,308 | $12K | |
| 2019 | 3,000 | $6K | |
| 2020 | 11,423 | $8K | |
| 2021 | 12,196 | $25K | |
| 2022 | 25,513 | $75K | |
| 2023 | 44,998 | $88K | |
| 2024incomplete | 86,403 | $47K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.2% | 10,349 | 9,921 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | 5.3% | 9,389 | 9,125 | $14K |
| 83970 | 4.9% | 3,348 | 3,315 | $13K | |
| 80053 | Comprehensive metabolic panel | 4.7% | 10,191 | 9,771 | $12K |
| 84481 | 4.1% | 8,264 | 8,050 | $11K | |
| 80061 | Lipid panel | 4.1% | 9,096 | 8,820 | $11K |
| 82607 | 4.0% | 6,469 | 6,278 | $11K | |
| 80074 | 4.0% | 3,469 | 3,391 | $10K | |
| 82746 | 3.9% | 8,542 | 8,340 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 3.7% | 9,397 | 9,125 | $10K |
| 82728 | 3.4% | 7,378 | 7,168 | $9K | |
| 84403 | 3.1% | 3,794 | 3,706 | $8K |
57 more codes
| 82670 | 3.0% | 2,870 | $8K | |
| 84144 | 2.5% | 3,490 | $7K | |
| 84439 | 2.3% | 8,505 | $6K | |
| 84402 | 2.2% | 2,509 | $6K | |
| 84153 | 2.2% | 3,474 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.1% | 1,989 | $5K |
| 83550 | 2.1% | 8,700 | $5K | |
| 82627 | 1.9% | 2,379 | $5K | |
| 83540 | 1.9% | 8,786 | $5K | |
| 83002 | 1.9% | 2,232 | $5K | |
| 83735 | 1.8% | 7,594 | $5K | |
| 83001 | 1.8% | 2,034 | $5K | |
| 84270 | 1.8% | 2,371 | $5K | |
| 82378 | 1.7% | 2,198 | $4K | |
| 86677 | 1.6% | 4,710 | $4K | |
| 83003 | 1.5% | 2,363 | $4K | |
| 86235 | 1.4% | 2,504 | $4K | |
| 83090 | 1.2% | 2,678 | $3K | |
| 84146 | 1.2% | 1,292 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 842 | $3K |
| 86225 | 1.1% | 2,781 | $3K | |
| 84550 | 1.1% | 7,150 | $3K | |
| 85652 | 1.0% | 6,686 | $3K | |
| 86431 | <1% | 6,456 | $2K | |
| 86038 | <1% | 2,367 | $2K | |
| 86140 | <1% | 5,430 | $2K | |
| 84154 | <1% | 1,596 | $2K | |
| 83690 | <1% | 3,355 | $1K | |
| 82150 | <1% | 2,403 | $1K | |
| 82533 | <1% | 924 | $1K | |
| 81000 | <1% | 1,513 | $909.09 | |
| 86003 | <1% | 550 | $836.15 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 842 | $662.14 |
| 0099U | <1% | 160 | $605.78 | |
| 82043 | <1% | 295 | $594.64 | |
| 82977 | <1% | 1,497 | $591.87 | |
| 82570 | <1% | 295 | $536.20 | |
| 84100 | <1% | 1,573 | $523.94 | |
| 82248 | <1% | 1,439 | $454.60 | |
| 87507 | <1% | 254 | $411.51 | |
| 86063 | <1% | 1,265 | $395.15 | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 311 | $359.83 |
| 86141 | <1% | 1,261 | $303.09 | |
| 87486 | <1% | 842 | $282.44 | |
| 87581 | <1% | 842 | $282.32 | |
| 85730 | <1% | 488 | $198.42 | |
| 82553 | <1% | 644 | $172.19 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 625 | $133.44 |
| 85610 | <1% | 488 | $127.30 | |
| 82785 | <1% | 275 | $91.89 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 95 | $57.56 |
| 86800 | <1% | 251 | $29.56 | |
| 86376 | <1% | 251 | $27.06 | |
| 83615 | <1% | 360 | $17.16 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 44 | $13.54 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 13 | $0.00 |
| 0097U | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBAGDASSARIAN, ONICK (PRESIDENT)